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SIGNIFICANCE OF INCREASED TISSUE TRANSGLUTAMINASE IN  
HORMONE REFRACTORY PROSTATE CANCER  
Publication No. ________  
Amy Lee Han, B.A.  
Supervisory Professor: Kapil Mehta, Ph.D.  
The progression of hormone responsive to hormone refractory prostate cancer 
poses a major clinical challenge in the successful treatment of prostate cancer. The 
hormone refractory prostate cancer cells exhibit resistance not only to castrate levels of 
testosterone, but also to other therapeutic modalities and hence become lethal. 
Currently, there is no effective treatment available for managing this cancer. These 
observations underscore the urgency to investigate mechanism(s) that contribute to the 
progression of hormone-responsive to hormone-refractory prostate cancer and to target 
them for improved clinical outcomes. 
Tissue transglutaminase (TG2) is a multifunctional pro-inflammatory protein 
involved in diverse physiological processes such as inflammation, tissue repair, and 
wound healing. Its expression is also implicated in pathological conditions such as 
cancer and fibrosis. Interestingly, we found that the androgen-independent prostate 
cancer cell lines, which lacked androgen receptor (AR) expression, contained high basal 
levels of tissue transglutaminase. Inversely, the cell lines that expressed androgen 
receptor lacked transglutaminase expression. This attracted our attention to investigate 
the possible role this protein may play in the progression of prostate cancer, especially in 
view of recent observations that its expression is linked with increased invasion, 
metastasis, and drug resistance in multiple cancer cell types. The results we obtained 
were rather surprising and revealed that stable expression of tissue transglutaminase in 
androgen-sensitive LNCaP prostate cancer cells rendered these cells independent of 
androgen for growth and survival by silencing the AR expression. The AR silencing in 
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TG2 expressing cells (TG2-infected LNCaP and PC-3 cells) was due to TG2-induced 
activation of the inflammatory nuclear transcription factor-κB (NF-κB). Thus, TG2 
induced NF-κB was found to directly bind to the AR promoter. Importantly, TG2 protein 
was specifically recruited to the AR promoter in complex with the p65 subunit of NF-κB. 
Moreover, TG2 expressing LNCaP and PC-3 cells exhibited epithelial-to-mesenchymal 
transition, as evidenced by gain of mesenchymal (such as fibronectin, vimentin, etc.) and 
loss of epithelial markers (such as E-cadherin, β-catenin). Taken together, these results 
suggested a new function for TG2 and revealed a novel mechanism that is responsible 
for the progression of prostate cancer to the aggressive hormone-refractory phenotype. 
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Chapter I: Background and Introduction 
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Prostate cancer is the second leading cause of death among American men, with 
nearly 218,000 new cases diagnosed every year and 32,000 deaths [1]. In general, 
normal and early-stage prostate epithelial cells depend on androgen-mediated signaling 
for their growth and survival. Androgens play an important role in regulating the growth, 
differentiation, and survival of prostate epithelial cell [2]. The androgen receptor (AR) is a 
nuclear receptor functioning as a steroid-hormone activated transcription factor directly 
regulating gene expression [3]. The AR contains three main domains [4]: the N-terminal 
regulatory domain (NTD), DNA-binding domain (DBD), and the ligand-binding domain 
(LBD) (Figure 1). The DBD and LBD are highly ordered and conserved among different 
species, while the NTD is more diverse [5]. The DBDs and LBDs of other members of 
the nuclear receptor super-family, such as the progesterone receptor and estrogen 
receptor are also highly conserved. Among the nuclear receptors, the DBD contains the 
greatest degree in homology, with more than 51% shared characteristics [6]. The AR, 
located on the X chromosome, is composed of 8 exons and coded by a gene that is 
longer than 90 kb [7]. There are two isoforms of the AR: AR isoform-1 contains the full 
length AR with a molecular weight of 110 kDa and AR isoform-2 differs in the 5’-UTR 
and coding region by lacking the first 187 amino acids; therefore, with a distinct and 
shorter NTD, it has a molecular weight of 87 kDa [8]. Practically half of the AR coding 
sequence represents the NTD, which regulates majority of the transcriptional activity [9]. 
The structure of the NTD could possibly change once bound to DNA or other proteins 
[10], suggesting that it could mediate the recruitment and assembly of co-regulators to 
mediate cell and gene specific effects [11]. The DBD is cysteine-rich and composed of 
two zinc finger motifs [12]: The first one mediates DNA recognition by interacting with 
specific base pairs of the androgen response elements [13] and the second mediates 
the dimerization of the AR as well as stabilizes the DNA bound complex [12]. The AR 
homodimer is arranged in a head-to-head fashion allowing further AR stabilization for  
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Figure 1. Schematic representation of androgen receptor (AR) gene.  
The AR gene is located on chromosome Xq11-12 and is longer than 90 kb. It consists of 
8 exons, which make up 3 distinct domains: N-terminal domain (NTD), DNA-binding 
domain (DBD), and the C-terminal ligand-binding domain (LBD). The DBD contains two 
zinc finger motifs and a C-terminal extension, which forms part of the hinge region. 
(Gelmann EP [7]. Reprinted with permission.  2008 American Society of Clinical 
Oncology. All rights reserved.) 
 
 
 
 
 
 
 
  4 
binding to DNA [14]. The transcriptional activation of AR is mediated by activation 
function 1 (AF1) and activation function 2 (AF2) [15]. While AF1 is located in the NTD, 
AF2 is located at the C-terminus inside the LBD. AF1 has a fairly weak transcriptional 
activation function where as AF2 is the primary region that mediates the transcriptional 
activation. The AR also contains a small hinge region located in between the DBD and 
LBD [16]. A nuclear localization signal (NLS) [17] resides within this region in addition to 
phosphorylation [18, 19], acetylation [20], and degradation sites [21]. Lastly, the LBD 
facilitates the binding of the androgens [22, 23], which induces the conformational 
change that results in the nuclear translocation, phosphorylation, homodimer formation, 
interaction with DNA, and transcriptional regulation of the target gene.  
Typically, in the cytoplasm, AR is bound by heat shock proteins (HSPs) [24] and 
is inactive. However, following its binding to the ligand androgen, it gets activated and 
undergoes a conformational change [25]. This change involves the dissociation of AR 
from HSPs, the LBD positioned in a way that prevents the dissociation of the ligand, and 
the NLS exposed. Thus, AR is released and targeted to the nucleus with the assistance 
of importins [26]. As a homodimer, the AR can then bind to specific androgen response 
elements, thereby activating transcriptional activity of genes needed for the growth and 
survival of the cells [27]. The AR specifically recognizes a 15 bp palindromic binding 
sequence motif in the promoter region of its target genes. This consensus sequence is 
composed of two hexameric half sites (5’-AGAACA-3’) separated by a 3-bp spacer (5’-
AGAACANNNTGTTCT-3’) [28]. Prostate specific antigen (PSA) [29] and insulin-like 
growth factor I (IGF-I) [30] are among the specific target genes regulated by the AR.  
Androgen ablation therapies (either surgical or chemical) represent the mainstay 
treatment for early stage prostate cancer [31]. Both castration [32] and the use of anti-
androgens [33] inhibit the transcriptional activation by blocking AR signaling. Surgical 
castration involves the removal of the testes, the major androgen producing organ. 
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Chemical castration involves the use of luteinizing hormone-releasing hormone (LHRH) 
agonists/antagonists [34]. LHRH is required for the production of androgen by the testes. 
It is released by the hypothalamus, travels to the pituitary gland, which releases the 
luteinizing hormone that signals the testes to make androgen [35]. Anti-androgens inhibit 
the transcriptional activity of the AR [36, 37]. Thus, this androgen blockade helps prevent 
the growth and spread of prostate cancer. However, within 2-5 years of remission, the 
cancer returns in majority of these patients and exhibits resistance not only to androgen 
ablation therapies, but also to other known chemotherapies and is highly metastatic 
(referred to as hormone refractory or castration resistant prostate cancer: H/CRPC), 
resulting in patients’ death [38]. Since there is no effective therapy for HRPC, 
understanding the mechanism(s) that contribute to the progression of hormone-
responsive to hormone-refractory prostate cancer may help identify new therapeutic 
strategies for better clinical outcomes.  
So far, three mechanisms have been linked to the development of HRPC. The 
first involves DNA-based alterations, such as mutations in or amplification of androgen 
receptor (AR) gene, although only a few patients fall into this category [39]. Studies have 
found AR mutations in HRPC that could enhance AR activation even with the low 
androgen levels [40] or by other steroid hormones such as progesterone [41] and 
glucocorticoids  [42]. These mutations could also in turn allow anti-androgens to behave 
as agonists [43]. Some of the AR mutations are commonly found in the LBD, possibly 
altering the ligand binding specificity to the AR [44]. For example, a threonine to alanine 
amino acid change at codon 877 (T877A) renders the mutated AR to bind and be 
activated by progesterone, estradiol, and anti-androgens [45]. In addition, a mutation of 
codon 741 of the AR could potentially enable the androgen antagonist, specifically 
bicalutamide, to behave as an agonist. Patients who have been treated with this anti-
androgen drug have shown to acquire this mutation [46, 47] as well as LNCaP cells that 
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have been long term cultured with bicalutamide [48]. On the other hand, the number of 
AR mutations found in patients who no longer respond to androgen ablation therapy are 
fairly low, approximately in 10% of patients with HRPC [46]. However, AR antagonists 
could confer selective pressures for the mutations that stimulate AR activity in addition to 
other mechanisms [49]. Amplification of the AR allows the prostate cancer to bypass the 
reduced levels of androgens by enhancing the number of androgen bound receptors. 
About 30% of patients show increased AR gene expression in tumors that have failed 
hormone ablation therapy while the primary tumors even within the same patients had 
no amplification prior to the therapy [50, 51]. High level of AR expression has the ability 
to compensate the reduced concentrations of androgens by maintaining enough 
activated AR for the continual growth and survival [52, 53]. Despite the type of DNA-
based alterations, whether mutation or gene amplification, these cells still require 
androgen or an alternative ligand binding to promote tumor progression. These cells 
have instead been able to establish a lower threshold for androgens by increasing their 
sensitivity and adjusting to the depleted levels of androgens [54].  
The second mechanism includes patients who do not have AR mutations or 
amplification, but still retain AR signaling even in the absence of androgen [39]. In these 
cases, alternative pathways are implicated leading to the activation of AR signaling [18]. 
For example, Her-2/neu-induced activation of AKT can promote AR activation by the 
phosphorylation of serine residues [55]. Her2/neu is a tyrosine kinase receptor from the 
epidermal growth factor family of receptors. Its overexpression has been implicated to 
play a role in promoting androgen independent growth of prostate cancer and activating 
AR signaling [56]. Prostate cancer xenograft models have even shown an upregulation 
of Her2/neu in HRPC [57, 58]. Studies have also found MAP kinases (MAPK) involved in 
the activation of AR signal transduction [59, 60]. MAPK signaling effectors can also 
activate AR signaling although only a couple have been identified and studied [38]. 
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Furthermore, Aurora-A, a serine/threonine protein kinase involved in mitosis 
progression, was shown to phosphorylate AR at Thr-282 and Ser-293 and potentiate its 
transactivation [61]. In comparison with normal tissue, prostate tumors have higher 
Aurora-A expression [62]. All these possible alternative intracellular kinase signaling 
suggests that the crosstalk between the different signaling pathways can lead to the 
continual activation of the AR without the assistance of androgens. HRPCs tend to 
express AR and the PSA gene [63], implying that the AR signaling pathway is still 
functionally maintained in these cells. 
The third mechanism involves a complete bypass of AR pathways as the cancer 
cells develop the ability to survive through alternative pathways [39]. Indeed, a recent 
study showed that a significant number of HRPC tumor samples from metastatic sites 
lacked AR expression [64]. It has been proposed that a subpopulation of the prostate 
cancer cells may already be independent of androgen prior to the hormone ablation 
therapy [65]. Since these cells would not be affected by the absence of androgens, only 
the androgen-dependent cells would be targeted. Thus, while the androgen-dependent 
cells would be abolished, the androgen-independent cells would continue to proliferate 
and thrive in the castrated environment. The basal, progenitor cells of the prostate are 
independent of androgen and their proliferation and death rates are unaffected by 
androgen ablation therapy [66] as is the case for advance prostate cancers, so it may be 
possible for the prostate tumors to adopt these prostate stem cell characteristics to resist 
apoptosis and proliferation [67]. In fact, one study demonstrated that the clonal 
expansion of androgen-independent cells at a frequency of approximately 1 per 105-106 
androgen-dependent cells resulted in late stage androgen independence [68]. It 
speculated that due to the heterogeneous nature of prostate cancer cells and their 
varying dependence on androgen, hormone ablation therapy induces selective pressure 
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that changes the relative frequency of these cells allowing the androgen independent 
cancer cells to expand and thrive [39]. 
  Tissue transglutaminase (TG2) is a pro-inflammatory protein belonging to the 
transglutaminase family of enzymes. It is a monomeric protein of 78 kDa, located on 
chromosome 20 and consists of 13 exons and 12 introns [69]. TG2 is structurally and 
functionally a complex protein implicated in multiple physiological processes such as 
apoptosis, wound healing, inflammation, and cell adhesion. TG2 catalyzes the cross-
linking of proteins through the transamidation of γ-glutamine residues to ε-lysine residues 
in a Ca2+ dependent manner [70]. Besides its crosslinking activity, TG2 can bind and 
hydrolyze GTP and ATP [71], catalyze protein disulfide isomerase reactions [72], 
function as a protein kinase [73], and behave as a scaffold protein interacting directly 
with other proteins, such as fibronectin [74] and integrin [75]. TG2 is composed of four 
distinct domains: an N-terminal β-sandwich domain, a catalytic core domain, and two C-
terminal β-barrel domains (Figure 2A) [70]. TG2 is predominantly an intracellular protein 
present in the cytosol, nucleus, and cell membrane [76]. However, there are some cases 
where TG2 is found secreted outside of the cell [77]. In general, under physiological 
conditions with low Ca2+ and high GTP concentrations, TG2 is kept in its inactive closed 
conformation state where the bound GTP keeps TG2 in its compact form, inhibiting the 
posttranslational crosslinking of proteins. It is in its inactive compact form that TG2 can 
behave as a scaffold protein participating in cell adhesion, cell survival, cell growth, 
invasion, and migration. It can interact with other proteins by altering their structure, 
function, and/or stability. However, under extreme stress or trauma, the disruption of 
Ca2+ homeostatic levels allows TG2 to be activated into its extended open conformation, 
exposing the catalytic transamidation site (Figure 2B). Thus, TG2 is able to crosslink 
intracellular proteins, leading to cell death [78]. TG2 plays an important role in wound 
healing [79, 80]. The cytokines and growth factors that are secreted during the initial 
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A 
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Figure 2. Schematic representation of tissue transglutaminase (TG2) structure and 
functions.  
A) The TG2 gene is located on chromosome 20 and consists of 13 exons, which make 
up 4 distinct domains: N-terminal β-sandwich domain, catalytic core domain, and 2 β-
barrel domains. (Adapted from Lorand L et al. [70] by permission from Macmillian 
Publishers Ltd: Transglutaminases: crosslinking enzymes with pleiotropic functions, 
copyright 2003). 
B) Under normal physiological conditions, the low Ca2+ and high GTP levels maintains 
TG2 in its compact inactive conformation where it can act as a scaffold protein 
participating in cell adhesion, survival, growth, invasion, and migration. However, under 
stressful conditions, the influx of Ca2+ can activate TG2 to be in its extended active 
conformation, allowing it to catalytically crosslink intracellular proteins leading to cell 
death. (Adapted from Mehta K et al. [96] copyright 2010, with permission from Elsevier). 
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stage of tissue injury can regulate the expression of TG2. For instance, transforming 
growth factor β1 (TGF-β1) induces TG2 expression in keratinocytes [81] and tumor 
necrosis factor α (TNF-α) has been seen to induce TG2 expression in liver cells [82]. At 
sites of injury, there is an increase in TG2 expression and activity at sites of 
neovascularization and in endothelial cells seeming to play a protective role [83, 84]; 
however, the continual TG2 expression can potentially lead to abnormal wound healing 
[80]. Cancer has been described as a wound that does not heal and tends to share 
many similarities with the inflammatory response and tissue repair that occurs upon 
tissue injury [85]. Inflammation has been found to assist in the progression of the tumor, 
promoting growth, survival, invasion, and metastasis of cancer cells [86]. TG2 has been 
implicated to play a role in advance-stage cancers where increased TG2 expression in 
cancer cells has been linked to poor patient survival [87, 88]. In fact, aberrant expression 
of TG2 has been linked with increased invasion [89], metastasis [87, 90], and drug 
resistance [87, 91] in multiple cancer cell types, including breast [92], ovarian [93], lung 
[94], and pancreatic [95] cancers. These characteristics also hold true for castration 
resistant prostate cancer where we see an increase in invasiveness, highly metastatic 
behavior, and drug resistance. In the present study, our findings address the significance 
of TG2 in hormone refractory prostate cancer. We examined whether TG2 plays a role in 
androgen-independent survival or growth using the loss- and gain-of-function approach. 
We show that aberrant expression of TG2 in prostate cancer cells promotes hormone 
refractoriness by silencing AR expression and promotes invasive phenotype by inducing 
epithelial-to-mesenchymal transition (EMT). Moreover, we provide a molecular 
mechanism by which TG2-induces the progression from androgen-dependent to 
androgen-independent cell growth and survival of prostate cancer cells. 
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Hypothesis and Specific Aims 
 
 Based on the recent findings that TG2 expression is frequently upregulated in 
multiple cancer cell types and its expression is associated with drug resistance and 
metastasis, our lab has been interested in determining the significance of TG2 in cancer 
development and progression. In this context, our preliminary observation that only two 
(PC-3 and DU-145) of the seven prostate cancer cell lines tested, showed high basal 
levels of TG2 expression (Figure 3, Fok J and Mehta K. Unpublished) is of significance. 
Inversely, the cell lines that lacked TG2 expression contained high basal expression of 
AR protein and transcript. These results implied that TG2 might play a role in the 
progression of androgen-dependent to androgen-independent prostate cancer by 
modulating AR expression and bypassing AR signaling for cell growth and survival. 
Based on these preliminary and interesting results, we hypothesized that aberrant 
expression of TG2 in prostate cancer cells could promote hormone refractoriness 
and confer drug resistance and metastatic phenotype. To test this hypothesis, we 
formulated the following two specific aims: 
Aim 1. To determine whether tissue transglutaminase (TG2) expression is 
necessary and/or sufficient in conferring androgen refractory phenotype in 
prostate cancer cells.  
Aim 2. To determine TG2-regulated pathways that contribute to the hormone 
refractory phenotype in prostate cancer cells.  
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Figure 3. The basal level of tissue transglutaminase (TG2) and androgen receptor 
(AR) expression in prostate cancer cell lines. 
TG2 and AR protein expression was determined in indicated prostate cancer cell lines 
using immunoblotting. Results show an inverse correlation between TG2 and AR 
expression. The prostate cancer cells with high AR expression, lacked TG2 expression. 
Conversely, the cell lines expressing high basal levels of TG2 lacked the AR expression. 
The TG2 expressing DU-145 and PC-3 cells are among the androgen-independent 
prostate cancer cell lines, suggesting that TG2 could play a role in hormone 
refractoriness. The membrane was reprobed with anti-GAPDH antibody to ascertain 
even protein loading.
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Cell Lines 
 The LNCaP and PC-3 cell lines were generously provided by Dr. Nora Navone 
(The University of Texas M.D. Anderson Cancer Center, Houston, Texas). Cells were 
maintained in RPMI 1640, supplemented with 10% fetal calf serum, 2 mmol/L L-
glutamine, and antibiotics. All media were purchased from Fisher Scientific (Pittsburgh, 
PA). 
 
TG2 Lentiviral Transfection 
 pCDH cDNA Cloning and Expression Lentivectors (SBI System Biosciences, 
Mountain View, CA) was used to stably transfect LNCaP cells with TG2 (Figure 4). 
Briefly, HEK 293 cells were co-transfected with a lentiviral expression construct and 
pPACK packaging plasmid mix to create TG2 lentiviral particles. Viral particles were then 
collected and used to infect the LNCaP cells. Stably transfected cells were established 
by selection with puromycin (Invivogen, San Diego, CA) at concentrations of 1 µg/ml. 
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Figure 4. Schematic representation for propagation of lentiviral particles. The 
packaging plasmids mix and TG2 expressing vector construct are transfected into the 
HEK 293 cells to create packaged TG2 lenti pseudoviral particles. These TG2 
pseudoviral particles can be collected from the HEK 293 medium as the over abundant 
production of these particles get secreted out into the cell culture medium. This medium 
is transferred over to the target cells (LNCaP) for infection. The selection for the 
successfully TG2 transfected cells is made by puromycin: Since the expression vector 
contains both the TG2 and puromycin resistant construct, only the TG2 transfected cells 
would be able to survive and withstand the presence of puromycin. (Reprinted with 
permission.  2007 System Biosciences (SBI): pCDH cDNA Cloning and Expression 
Lentivectors User Manual). 
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Cell Proliferation Assay 
 Cells (2,000) were plated in quadruplicates (200 µl media/well) in ninety-six well 
plates (2 plates). 8 wells were left empty for blank controls. 20 µl of 5 mg/ml MTT 
(Thiazdyl Blue Tetrazolium Bromide, M2128-1G, Sigma Aldrich, St Louis, MO) dissolved 
in PBS was added to each well of one ninety-six well plate 2 hours after plating and left 
in the incubator (37°C, 5% CO2) for 4 hours. Media was removed and 200 µl of Dimethyl 
Sulfoxide (DMSO) (Sigma) was added to dissolve the formazan. Plate was mixed 
thoroughly for 5 minutes and optical density read at 570 nm. This served as the baseline 
to evaluate the relative cell growth. Cells of the other ninety-six well plate were kept in 
the incubator for 3 days in which MTT solution was added 4 hours prior to resuspending 
the formazan with DMSO and reading the optical density. 
 
Cell Growth  
 Cells (2,000) were added in quadruplicates to ninety-six well plates and 
incubated overnight to allow the cells to attach to the wells. Either 0.1 nM R1881 (AR 
agonist, Sigma) or 50 µM of bicalutamide (AR antagonist, Sigma) was added to the cells 
and left in the incubator for 48 hours. The number of viable cells remaining at the end of 
the treatment was determined using MTT: 20 µl of 5 mg/ml MTT dissolved in PBS was 
added to each sample well. After 4 hours, media was removed and 200 µl of DMSO was 
added to dissolve the formazan. Plate was mixed thoroughly for 5 minutes and optical 
density read at 570 nm. The untreated cells (only complete growth medium) served as 
the baseline to evaluate the relative number of cells. 
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Drug Response Assay 
 Cells (2,000) were plated in quadruplicates to ninety-six well plates and 
incubated overnight for the cells to adhere to the wells. After 24 hours, the medium was 
replaced with increasing concentrations of doxorubicin (0-0.1 µg/ml) (Sigma). The 
number of viable cells was measured 72 hours after drug treatment using MTT as 
mentioned previously. 
 
Immunoblotting 
 Cells were grown in 100-mm dishes up to 80% confluence, washed twice with 
cold phosphate-buffered saline (PBS). Nuclear and Cytoplasmic Extraction Reagents 
(Thermo Scientific, Rockford, IL) was used to obtain nuclear protein. Otherwise, cells 
were lysed using NP-40 Lysis Buffer (50 mM Tris-HCl, 150 mM NaCl, and 0.5% NP-40, 
pH 7.5) containing 1:100 protease inhibitor cocktail (Roche Diagnostics, 11697498001, 
Mannheim, Germany). Cells were scraped and collected into a 1.5 ml eppendorf tube. 
Centrifuged at 13,000g for 10 minutes at 4°C. The supernatant was collected and 
measured for their protein concentration using Bio-Rad Protein Assay. 30 µg of protein 
was resolved in an 8-10% reducing gradient polyacrylamide gel (PAGE). Proteins were 
transferred onto a nitrocellulose membrane and after blocking with 5% non-fat milk or 
3% BSA probed with appropriate primary antibody: anti-TG2 (Abcam, CUB7402, 
1:10,000, Cambridge, MA), anti-αβ-actin (mAbcam 8226,1:5000), anti-AR (Santa Cruz, 
N-20, 1:1000, Santa Cruz, CA), anti-E-cadherin (Santa Cruz, sc-21791, 1:1000), anti-
fibronectin (Santa Cruz, sc-71116, 1:1000), anti-β-catenin (BD Biosciences, 610153, 
1:3000, San Jose, CA), anti-NF-κB p65 (Santa Cruz, sc-109, 1:1000), and anti-IκBα 
(Imgenex, IMG-127A, 1:3000, San Diego, CA). The antigen-antibody reaction was 
detected using the appropriate horseradish peroxidase-conjugated secondary antibody, 
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followed by visualization with the electrochemiluminescence detection system (Denville 
Scientific Inc., Metuchen, NJ). 
 
Reverse Transcriptase-Polymerase Chain Reaction 
 Cells were plated on 100-mm tissue culture dishes and grown to 70% 
confluence, washed with PBS, and used to isolate total RNA by the RNeasy Mini Kit 
(Qiagen, Valencia, CA) according to the manufacturer’s protocol. RNA concentration 
was measured using a Nanodrop Spectrophotometer. 5 µg of total RNA was used to 
synthesize cDNA through SuperScript First-Strand Synthesis System for RT-PCR 
(Invitrogen, Carlsbad, CA). PCR was then conducted with the cDNA using the specified 
conditions: Samples were incubated at 94°C for 5 minutes, then 35 cycles of PCR was 
performed under optimized conditions (denaturation at 94°C for 45 sec, refer to Table 1 
for annealing temperatures for 30 sec, extension was at 72°C for 1 min 30 sec), and 
stored in 4°C. PCR samples were run on a 1% Agarose (Denville Scientific Inc.) gel in 
TBE with added ethidium bromide. Bands were viewed under UV light and images 
captured using Alpha Innotech FluorChem 8900. 
 
 
  19 
 
Table 1. RT-PCR primer sequences. 
The forward and reverse primer sequences respectively used for the RT-PCR reactions. 
Included are the PCR product sizes and the annealing temperature implemented to run 
the PCR amplification. Primers were ordered from Invitrogen. 
 
Immunofluorescence 
 Cells (1000) were plated in Chamber Polystyrene Vessel slides (Fisher Scientific) 
and left in the incubator. Media was changed the next day. At 70% confluence, cells 
were washed 3 times with 1x DPBS. Cells were fixed in 4% paraformaldehyde for 10 
minutes, permeabilized with 100% ice-cold methanol for 10 minutes at RT. Blocked for 1 
hour in blocking solution (3% BSA, 1% Normal Animal Serum). Cells were incubated 
with the appropriate primary antibody (1:100) in blocking solution overnight at 4°C. 
Appropriate secondary antibody (Alexa Fluor 488/546 goat anti-rabbit/mouse IgG, 1:150, 
Invitrogen) was added for 1 hour at RT. Then stained with 0.5 µg/ml DAPI (Molecular 
Probes, D-1306, Invitrogen) for 5 minutes. Chambers were removed and cells were 
mounted on glass cover slips using anti-fade mounting media (DakoCytomation, S3023, 
Carpinteria, CA). Slides were left to dry and sealed with nail hardener polish. Between 
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every step, cells were washed three times with 1x DPBS. Images were viewed and 
captured using a Nikon Eclipse fluorescence microscope (Melvilled, NY). 
 
Cell Invasion 
 Invasion was determined in vitro using Matrigel-transwell inserts. Cells were 
plated in 100-mm culture dishes. At 70% confluence, cell plates were rinsed with 1x PBS 
and serum free media was added to each plate and incubated overnight in the 37°C CO2 
incubator. Matrigel (Fisher, CB40234) was thawed on ice overnight. Transwell inserts 
with 8.0-µm pore size were coated with 200 µl of a 0.7 mg/ml concentration of Matrigel in 
cold serum-free medium and placed in the incubator for 40 minutes to solidify. 
Meanwhile, cells (after 24 hours in serum free media) were washed with 1x PBS then 
trypsinized. Cells were washed 3 times in serum-free media and pellet was subsequently 
resuspended in serum-free medium. Before plating cells, media was aspirated from each 
transwell. 500 µl (0.2 million cells) of the cell suspension was added to duplicate wells. 
After 72 hours of incubation, Matrigel was gently removed from wells and cells that 
invaded through the membrane were stained using Hema-3 manual staining system 
(Fisher, 22-1229-11), mounted on a glass slide, and counted using a light microscope. 
Five fields of cells were counted for each well, and the mean number of cells per field 
was calculated. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
 EMSA was conducted to determine NF-κB activation. Nuclear extracts were 
obtained from cells (1.5x106 cells/ml) and incubated with 32P end-labeled 45-mer double 
stranded NF-κB oligonucleotides (15 µg of protein containing 16 fM of DNA) from the 
HIV long terminal repeat, 5’-TTGTTACAAGGGACTTTCCG 
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CTGGGGAC-TTTCCAGGGAGGCGTGG-3' (with NF-κB binding sites in bold) for 30 
minutes at 37°C. The DNA-protein complex was run on a 6.6% native polyacrylamide gel 
to separate the complex from free oligonucleotides. Gel was left to dry and then 
visualized using a Storm 820 Phosphor Imager. Radioactive bands were quantified using 
Image Quant Software (GE Healthcare). 
 
qPCR Array for NF-κB Target Genes 
 Cells were plated in 6-well plates. At 70-80% confluence, RNA was extracted 
using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. cDNA was 
synthesized using the RT2 First Strand Kit (SABiosciences, Frederick, MD). 91 µl of H2O 
was added to each 20 µl of cDNA synthesis reaction. The 12 RT2 Profiler customized 
PCR Array was purchased from SABiosciences. The PCR mix for each sample (12.5 µl 
RT2 SYBR Green/Fluorescein qPCR Master Mix, 11.5 µl H2O, and 1 µl template cDNA) 
would be added to each of the12 chosen gene-specific PCR primer pair containing wells: 
Zeb1, Zeb2, Twist, SNAI, COX2, IκB, iNOS, MTA-1, HOMX1, CDKN1, CCND1, iCAM1, 
COPS2. The two-step cycling program for BioRad iCycler was used for 95°C, 10 min; 40 
cycles of (95°C, 15 sec; and 60°C, 60 sec). The real-time thermal cycler was 
programmed to detect and record the SYBR Green signal from every reaction at the end 
of the 60°C annealing/extension step for each cycle. 
 
Knockdown of p65 and TG2 by gene-specific siRNA 
 Cells (300,000) were plated into six-well plates and left to adhere overnight. Cells 
were transfected with 2µg of either NF-κB p65 siRNA (Cell Signaling, #6535, Danvers, 
MA), TG2 siRNA (sense: 5’-GGGCGAACCACCUGAACAATT-3’, antisense: 5’-
UUGUUCAGGUGGUUCGCCCTT-3’, Qiagen), or non-specific siRNAs using 
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oligofectamine (Invitrogen). After removing medium from the cells, 2 ml of OPTIMEM 
(Invitrogen) was added and cells were left in the incubator. Meanwhile, siRNA mix was 
prepared as follows: In one 1.5 ml tube, 5 µl of siRNA was added to 155 µl of OPTIMEM, 
in a separate 1.5 ml tube, 8 µl oligofectamine + 32 µl OPTIMEM and left in RT for 15 
minutes. Then added the siRNA/OPTIMEM mix into the tube with oligofectamine, which 
was mixed and left at RT for 30 minutes. The 2 ml of OPTIMEM was removed from the 
cells; 800 µl of new OPTIMEM was added, followed by the addition of the siRNA mix 
drop-by-drop into the well. 1 ml of normal growth media was added to the cells 24 hours 
after transfection and lysed 4 days after the initial transfection for immunoblotting. 
 
Chromatin Immunoprecipitation (ChIP) Assay 
 Chromatin Immunoprecipitation Assay (Figure 5) was performed using the ChIP 
Assay Kit (Millipore, catalog #17-295, Temecula, CA) according to supplier’s protocol. 
Cells were plated on 100-mm culture dishes to 70% confluence, treated directly with a 
final concentration of 1% formaldehyde (270 µl of 37% formaldehyde into 10 ml of 
complete growth medium on plate), and incubated for 10 minutes at 37°C to cross link 
histones to DNA. Medium was aspirated from the cells and washed twice using ice cold 
PBS. Cells were then scraped into 15 ml tube and pelleted for 4 minutes at 2000 rpm at 
4°C. Meanwhile, SDS Lysis Buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) was 
warmed to RT. Protease inhibitors were added to the SDS Lysis Buffer with a 
concentration of 50 µl/ml. PBS removed completely and cell pellet resuspended in 200 µl 
of SDS Lysis Buffer and incubated for 10 minutes on ice. DNA was sheared to lengths 
between 200 and 1000 base pairs through sonication conditions of six x10-second 
continuous pulses with 30 seconds interval between each pulse and centrifuged for 10 
minutes at 13,000 rpm at 4°C. Supernatant was transferred to a new 2 ml 
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microcentrifuge tube. 50 µl protease inhibitor was added per 1 ml of ChIP Dilution Buffer 
and used to dilute sonicated cell supernatant 10 fold (add 1800 µl ChIP Dilution Buffer to 
200 µl of sonicated cell supernatant = total volume of 2 ml). Saved a portion of the 
diluted cell supernatant (~20 µl) to use as input. 30 µl of immunoprecipitating antibody, 
anti-NF-κB p65 (Santa Cruz, sc-109) or anti-TG2 (NeoMarkers, MS-279-P1, Fremont, 
CA), were added to the 2 ml supernatant fraction and incubated overnight while rotating 
at 4°C. Next day, collected antibody/histone complex by adding 60 µl of Protein A 
Agarose/Salmon Sperm DNA for one hour at 4°C with rotation. Agarose was pelleted 
using gentle centrifugation at 1000 rpm for 1 minute. Carefully removed supernatant, 
containing unbound, non-specific DNA, and washed agarose/antibody/histone complex 
for 4 minutes while rotating with 1 ml of each of the following buffers respectively: Low 
Salt Immune Complex Wash Buffer (1x), High Salt Immune Complex Wash Buffer (1x), 
LiCl Immune Complex Wash Buffer (1x), and TE Buffer (2x). Added 250 µl of freshly 
prepared elution buffer (1% SDS, 0.1 M NaHCO3) to the pelleted complex to elute the 
histone complex from the antibody. Incubated at room temperature and vortexed 
intermittently to mix for 15 minutes. Spin down agarose by centrifugation at 1000 rpm for 
2 minutes and transferred supernatant fraction to another tube. Repeated elution once 
more for a combined total eluates volume of 500 µl. 20 µl of 5 M NaCl was added to the 
combined elutes including the input saved the day prior and heated at 65°C for 4 hours 
to reverse the histone-DNA crosslinks. After the addition of 10 µl of 0.5 M EDTA, 20 µl 1 
M Tris-HCl, pH 6.5, and 2 µl of 10 mg/ml Proteinase K, eluates were incubated for one 
hour at 45°C. DNA was recovered by phenol/chloroform extraction and ethanol 
precipitation. 2 µl of pellet paint co-precipitant (Novagen, Darmstadt, Germany) was 
used to visualize the DNA pellet and washed with 70% ethanol and air-dried. Pellet was 
resuspended in RNase free water. DNA was then subjected to PCR amplification using 
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primers as described previously [97], corresponding to the AR promoter from -38 to 
+246: 5’-GACCCGACTCGCAAACTGTT and 5’-CCTCCGAGTCTTTAGCAGCT as well 
as -760 to -460: 5’-GGGTGATTTTGCCTTTGAGA and 5’-
CATGACCAAGCCAGCAGATA. Primers corresponding to exon 1 (2403 to 2647) of the 
AR were to use as negative control: 5’-CCTGGCACACTCTCTTCACA-3’ and 5’-
GGATAGGGCACTCTGCTCAC-3’. Samples were run under the following conditions: 
94°C for 5 minutes, 37 cycles of PCR was performed (94°C- 45 sec, 60°C- 30 sec, 
72°C- 1 min), and then stored in 4°C. PCR samples were analyzed by agarose gel 
electrophoresis.  
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Figure 5. Scheme for chromatin immunoprecipitation (ChIP) assay.  
Cells were incubated at 37 °C with formaldehyde for 10 minutes to crosslink the protein 
to DNA. After the cells were washed with cold PBS and lysed with SDS Lysis Buffer, 
they were subjected to sonication of six, 10 second long pulses to shear the DNA into 
fragments. These fragments were incubated overnight with anti-NF-κB (p65) or anti-TG2 
antibody. The next day, the bound antibody/histone complex would be captured with 
protein A agarose beads, which would be collected and washed. The histone complex 
will be eluted from the antibody and reverted to decrosslinking. DNA would then be 
extracted, purified, and subjected to PCR analysis. (Adapted with permission.  2009 
Affymetrix: USB ChIP Assay Procedure). 
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Overexpression of TG2 in LNCaP Cells 
 Multiple studies have supported that the aberrant expression of tissue 
transglutaminase is associated with drug resistance and metastasis in many cancer cell 
types. HRPCs display similar characteristics in that they are more aggressive, drug 
resistant, and metastatic and display high basal levels of TG2 (Figure 3). To determine 
the significance of TG2 expression in HRPC, we first stably transfected the LNCaP cells 
with TG2 using the lentiviral construct (Figure 6A). The parental LNCaP cells are 
androgen-dependent and have no detectable expression of TG2 but expressed high 
levels of AR. We first tested for the response of TG2-transfected LNCaP cells to 
androgen (R1881, 0.1 nM) and androgen antagonist (Bicalutamide, 50 µM) in charcoal-
stripped serum containing RPMI medium. As expected, both the control and empty 
vector transfected LNCaP cells showed increase in cell growth and survival when 
incubated in the presence of androgen (R1881). Conversely, these cells showed 
significant reduction in growth and survival when incubated with AR antagonist, 
bicalutamide (Figure 6B). Interestingly, under identical conditions the TG2-transfected 
LNCaP cells showed no effect on cell growth or cell survival in response to either R1881 
or bicalutamide treatment. Cell growth in cultures treated with either agent was similar to 
the untreated cells. These results implied that TG2 expression could promote cell growth 
and survival in absence of androgen, and thus confer androgen-independent phenotype 
in LNCaP prostate cancer cells. TG2 expression by itself had no affect on cell growth, as 
determined by cell proliferation assay using MTT (Figure 7). The relative cell growth of 
control (vector-transfected or non-transfected) LNCaP cells was comparable to TG2 
transfected cells as determined by MTT assay.
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Figure 6. TG2 expression renders the LNCaP cells independent of androgen for 
their growth and survival.  
A) Western blot analysis of the control (parental or empty vector) and TG2 transfected 
LNCaP cells. The LNCaP cells with stable TG2 expression were established by lentiviral 
infection containing TG2 construct and selection against puromycin (1µg/ml). 
B) These cells were subjected to either androgen agonist (R1881, 0.1 nM) or antagonist 
(Bicalutamide, 50 µM) to test for their response to androgen. Both control and empty 
vector LNCaP cells demonstrate an increase in growth upon the addition of androgen; 
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however, growth was inhibited by the presence of androgen antagonist. On the other 
hand, the LNCaP TG2 cells neither grew in response to R1881 nor displayed an 
inhibition of growth with bicalutamide. Results shown are means of quadruplicate values 
± standard deviation. The significance of difference (p-value) was calculated using the 
student’s t-test and is a comparison between the response either to androgen or 
androgen antagonist. A p-value less than 0.05 was considered significant.
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Figure 7. Expression of TG2 does not affect the overall proliferation rate. 
The parental, empty vector, and TG2 transfected LNCaP cells were analyzed for their 
cell proliferation rate using MTT assay. This was conducted to determine whether TG2 
expression had any affect on the proliferation of LNCaP cells. The cells were left in the 
incubator for 48 hours and the baseline was taken 6 hours after plating the cells. 
Absorbance was measured at 570nm. Results indicate a fairly similar cell proliferation 
rate amongst the cell lines. Results shown are means of quadruplicate values ± standard 
deviation from a representative experiment. Experiments were repeated at least twice 
displaying similar results.
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TG2 Induces Changes in Morphology 
TG2 expression was associated with noticeable changes in the morphology of 
LNCaP cells (Figure 8). The parental and empty vector-LNCaP cells grew clustered 
together with cell-to-cell contacts, the characteristic feature of epithelial cells. The 
LNCaP-TG2 cells, in contrast, grew more separated from each other, with fibroid-like 
appearance. These changes in the morphology indicated that TG2 expression might 
induce the transition of LNCaP epithelial cells to the mesenchymal state (EMT).  
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Figure 8. TG2 expression is associated with morphological changes. 
Images of the prostate cancer cell lines captured using the Nikon Eclipse Microscope 
(20x) at 60-70% confluence. LNCaP control and empty vector cells tend to grow 
clustered together, displaying high cell-to-cell contact, characteristic of epithelial-like 
cells. TG2-transfected cells, in contrast, grow separated from each other, demonstrating 
loss of cell adhesion, which is indicative of mesenchymal cells. LNCaP-TG2 cells 
resembled PC-3 cells, which contain high endogenous basal levels of TG2. These 
morphological changes seem to suggest that TG2 expression may play a role in 
inducing the epithelial-to-mesenchymal transition (EMT).
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TG2 Expression Promotes Epithelial-to-Mesenchymal Transition 
 To validate whether TG2-induced changes in the morphology of LNCaP cells is 
related to their transition into mesenchymal state, we determined various EMT-related 
markers in these cells. The results confirmed and were consistent to the differences 
seen between the cell morphology. There was a clear loss of E-cadherin in TG2 
transfected cells, which is one of the primary characteristics of cells undergoing the 
epithelial-mesenchymal transition (Figure 9A). There is also a decrease in β-catenin 
protein levels, as well as a gain in fibronectin, a mesenchymal marker. The PC-3 cells 
were used in parallel as a control to compare TG2-induced changes in LNCaP cells. The 
PC-3 cells also displayed a mesenchymal phenotype with absence of E-cadherin 
expression and presence of fibronectin. However, the PC-3 cells displayed high 
expression of N-cadherin, whereas no expression of N-cadherin was evident in TG2 
expressing LNCaP cells. Although the PC-3 cells display many similarities with the 
LNCaP TG2 cells, they do slightly deviate from each other. This suggests that TG2 
expression can partially promote the EMT phenotype in prostate cancer cells. 
Furthermore, these distinctive EMT markers are not only seen at a protein level, but also 
evident at a transcriptional level (Figure 9B). We also observed gain of other key 
mesenchymal markers, such as vimentin, Zeb1, and Zeb2 in TG2 expressing LNCaP 
cells. Especially, the increase in the Zeb1 transcriptional repressor was remarkable. The 
expression of EMT-related transcripts in the PC-3 cells followed similar pattern as the 
TG2-LNCaP cells. Immunofluorescence staining further confirmed the EMT-related 
changes in TG2-LNCaP cells and confirmed the loss of E-cadherin and gain in 
fibronectin (Figure 9C). In addition, while β-catenin expression in the LNCaP cells is 
membranous, β-catenin expression is nuclear in the LNCaP TG2 cells, which is 
indicative of the loss of E-cadherin. The androgen-independent PC-3 cells show 
comparable expression levels of fibronectin as well as a lack of E-cadherin expression. 
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Thus, these results strongly support that aberrant expression of TG2 promotes the EMT 
phenotype in prostate cancer cells.
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Figure 9. TG2 expression induces EMT in prostate cancer cells.  
A) Protein extracts were collected from each of the individual LNCaP (control, empty 
vector, and TG2-transfected) and PC-3 cells to evaluate the expression of EMT markers 
such as E-cadherin, β-catenin, N-cadherin, and fibronectin using immunoblotting. A 
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complete loss of E-cadherin, decrease in β-catenin, (epithelial cell markers), and gain in 
fibronectin expression (mesenchymal cell marker) by TG2-infected LNCaP cells 
suggested acquisition of the EMT phenotype. PC-3 cells with high basal TG2 levels, 
displayed similar EMT-related changes, except that PC-3 cells also showed increase in 
N-cadherin expression (another mesenchymal marker). 
B) RNA extracts were collected from each of the individual LNCaP (control, empty 
vector, and TG2-transfected) and PC-3 cells to evaluate the transcript levels of epithelial 
and mesenchymal markers. Results seem to coincide with immunoblot analysis - the 
loss in epithelial (E-cadherin) and gain in mesenchymal marker transcripts (vimentin, 
zeb1, zeb2). 
C) Cells were subjected to immunofluorescence staining. Once fixed with 
paraformaldehyde, cells were incubated with anti-TG2, anti-E-cadherin, anti-β-catenin, 
or anti-fibronectin antibody. Alexa 546 anti-mouse IgG (red) or Alexa 488 anti-mouse 
IgG (green) was used to detect the antigen-antibody reaction. DAPI was used to stain 
the nuclei. Immunostaining results further supported the loss of epithelial markers (E-
cadherin and β-catenin) and gain in mesenchymal marker (fibronectin) associated with 
TG2 expression. 
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TG2 Expression Promotes Cell Invasion in LNCaP Cells 
EMT has also been associated with an increase in cell invasiveness. Also, TG2 
expression has been found to promote invasion in many cancer cell types. Therefore, we 
next determined the invasive ability of TG2 expression on LNCaP cells. The 
invasiveness was determined using Matrigel-transwell inserts in either 10% fetal calf 
serum (FCS) or androgen-depleted 10% charcoal stripped serum (CSS) containing 
medium. Regardless of the type of serum medium used, LNCaP-TG2 expressing cells 
were 70-90% more invasive compared to the control or empty vector transfected LNCaP 
cells (Figure 10A). These results suggested that TG2-induced EMT in LNCaP cells is 
associated with increased invasiveness and this increased invasiveness is independent 
of androgen as revealed by the increased invasion of cells even in CSS medium (Figure 
10B). These results indicated that TG2 expression could promote invasion in prostate 
cancer independent of androgen signaling. 
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Figure 10. TG2 expression promotes cell invasion. 
A) Control, empty vector, and TG2 expressing LNCaP cells were subjected to an in vitro 
Matrigel-transwell invasion assay. Cells were serum-starved for 24 hours and then 
seeded on top of the matrigel-transwell. The cells were placed in either 10% fetal calf 
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serum (FCS) or charcoal-stripped serum (CSS) medium. After 72 hours, membranes 
were fixed, stained, and mounted to glass slides. The number of invaded cells in 5 
random microscopic fields was counted. Data shown are the mean number of cells 
invaded/field ± standard deviation. LNCaP TG2 cells were significantly more invasive 
than the control and empty vector cells in both the FCS and CSS medium. The 
significance of difference (p-value) was calculated using the student’s t-test and the p-
value less than 0.05 was considered significant. 
B) Images of the stained membranes with invaded cells through the membrane of the 
Matrigel-transwell inserts from a representative field. LNCaP TG2 cells show a greater 
number of invaded cells in comparison with the control and empty vector cells. The 
invasive ability of LNCaP-TG2 was comparable with that of PC-3 cells. 
  40 
Tissue Transglutaminase Expression Confers Drug Resistance 
An increase in drug resistance is a common feature associated with EMT. In 
addition, TG2 expression has been shown to confer drug resistance in multi-cancer 
types. Thus, we used an MTT assay to assess the drug response of the LNCaP cells. 
Different doses of increasing concentrations of doxorubicin (0-0.1 µg/ml) were added to 
the cells and the number of viable cells was measured after three days (Figure 11). 
Results reveal that TG2 expression is able to confer drug resistance in the LNCaP cells 
equivalent to the PC-3 cells, which contain high endogenous TG2 expression. These 
results demonstrate that TG2 expression can confer drug resistance in prostate cancer, 
characteristic of cells undergoing EMT and of HRPC.  
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Figure 11. TG2 expression confers drug resistance. 
Dose-response was conducted using MTT assay to determine the effect of doxorubicin-
induced cell death in the prostate cancer cells. After overnight culture, increasing 
concentrations of doxorubicin (0-0.1 µg/ml) were added to quadruplicate wells of 96-well 
plates containing indicated cells. The cells were incubated with the drug for 3 days and 
the number of viable cells remaining after the incubation was determined by MTT assay. 
The untreated cells served as control and baseline for comparison and the relative 
percent of viable cells is graphed and presented. Results are means of quadruplicate 
values ± standard deviation from a representative experiment. Experiments were 
repeated at least twice with similar results. 
 
 
0 
20 
40 
60 
80 
100 
120 
control 0.0025 0.005 0.0125 0.025 0.05 0.1 
R
el
at
iv
e 
C
el
l V
ia
bi
lit
y 
(%
) 
Doxorubicin, ug/ml 
LNCaP 
LNCaP 
TG2 
PC3 
  42 
 
 
 
 
 
 
 
 
 
 
 
Chapter III: Results 
(Specific Aim 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  43 
TG2 Results in the Loss of Androgen Receptor Expression 
 As discussed in the background data, there was an inverse correlation between 
TG2 and AR expression: Whereas the LNCaP cells lacked TG2 expression, but had high 
AR expression, the PC-3 cells contained high basal levels of TG2, but lacked AR 
expression. Therefore, we were curious to determine the effect of TG2 on AR 
expression. To our surprise, we found a complete loss of the AR in the LNCaP-TG2 cells 
(Figure 12A). The loss in AR expression of LNCaP cells was not only at the protein level, 
but also at the transcript level (Figure 12B). These findings suggested that TG2-
mediated silencing of the AR is occurring at the transcriptional level. The loss of AR 
confirmed that TG2 overexpression could bypass the AR signaling pathway completely 
allowing the progression of the androgen-dependent to androgen-independent prostate 
cancer. The loss of AR in TG2 expressing LNCaP cells was further validated by 
immunofluorescence staining (Figure 12C). Control and vector-infected cells showed 
significant staining for AR in the cytoplasm and in the nuclei while the TG2-infected cells 
completely lacked the AR expression. 
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Figure 12. TG2 expression is associated with loss of androgen receptor 
expression.  
A) Immunoblot analysis revealed a complete loss of the androgen receptor in LNCaP 
cells in response to TG2 expression.  
B) RT-PCR results further confirmed the loss of androgen receptor in TG2 expressing 
LNCaP cells at transcript level. 
C) Immunofluorescence staining shows high AR staining in the LNCaP cells, particularly 
inside the nucleus, which indicates that AR is activated in these cells. However, TG2 
expression in the LNCaP cells was associated with lack of AR expression. PC-3 cells, 
which contain high basal levels of TG2 also lacked AR expression. Cells were fixed with 
paraformaldehyde and incubated with anti-TG2 and anti-AR antibody. Alexa 488 anti-
  45 
mouse IgG (green) or Alexa 546 anti-rabbit IgG (red) were used to detect the antigen-
antibody reaction. DAPI was used to stain the nuclei.
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TG2 Induces NF-κB Activation in Prostate Cancer Cells 
 Since TG2 itself is not a transcription factor, it was unlikely that TG2 could 
directly silence the AR expression. So we reasoned that TG2 could affect the AR 
silencing either by modulating the expression of some transcription factors that then 
silences AR expression or it can do so by associating with some transcription factor to 
modulate its transcriptional activity. Indeed, TG2 expression has been linked with 
constitutive activation of NF-κB, the inflammatory transcription factor that is known to 
regulate genes involved in EMT, drug resistance, and metastasis. In line with this 
observation, there have been reports documenting the high NF-κB activation in 
androgen-independent cells compared to androgen-dependent prostate cancer as well 
as in metastatic prostate cancer versus the localized disease. Apart from these reports, 
NF-κB consensus sequences have been found in the AR promoter. In fact, Ko et al. [97] 
recently showed that TNFα-induced activation of NF-κB could negatively regulate AR 
expression. Based on these observations, we first determined if NF-κB is indeed 
activated in TG2-infected LNCaP cells. Electrophoretic mobility shift assay (EMSA) to 
determine basal activation levels of NF-κB revealed high NF-κB activity in LNCaP-TG2 
and in PC-3 cells (Figure 13). The vector-infected cells showed no significant NF-κB 
activity. NF-κB activity in TG2-infected cells was further validated by immunoblotting, 
using the nuclear and cytoplasmic protein extracts from these cells (Figure 14). While no 
detectable p65 subunit of NF-κB could be observed in the nuclear extracts from vector-
infected cells, a strong band for p65 was observed in TG2-infected LNCaP and PC-3 
cells. The presence of p65 in nuclear extracts indicated that NF-κB was indeed activated 
in the TG2 expressing cells whether TG2 expression was induced or endogenous. 
Immunofluorescence staining further confirmed significant translocation of p65 subunit in 
the nuclei of LNCaP-TG2 cells compared to the LNCaP-vector cells (Figure 15). 
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Similarly, PC-3 cells displayed high expression of p65 localization in the nucleus. 
Transfection of PC-3 cells with TG2 shRNA to knockdown endogenous TG2 expression 
showed significant decrease in p65 levels in the nuclei, despite the fact that we were 
only able to achieve 70% knockdown of TG2 in PC-3 cells.    
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Figure 13. TG2 expression results in constitutive activation of NF-κB in prostate 
cancer cells. 
The control (empty-vector) and TG2-transfected LNCaP cells as well as PC-3 cells (with 
endogenous expression of TG2) were analyzed for NF-κB activity by EMSA (in 
collaboration with Dr. Aggarwal’s laboratory, MD Anderson Cancer Center, Houston, 
TX). The nuclear extracts were isolated from the cells and incubated with 32P end-
labeled double stranded NF-κB oligonucleotides. Results show NF-κB activated in the 
TG2 containing prostate cancer cells, whether transfected with or endogenously 
expressing TG2. Center lane shows the TNF-α induced NF-κB activation as positive 
control (P.C.). Data show a 3-fold increase in NF-κB activation in TG2-transfected 
LNCaP cells. 
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Figure 14. Further validation of NF-κB activation in TG2 expressing cells. 
Nuclear and cytoplasmic protein extracts were taken from each of the individual cell lines 
and subjected to immunoblotting. Since inactive NF-κB is found in the cytoplasm and it 
is only the activated NF-κB that translocates to the nucleus, we evaluated the nuclear 
translocation of the p65 subunit of NF-κB in TG2 expressing cells. The results obtained 
consistently revealed the presence of p65 subunit inside the nucleus but only in TG2 
expressing cells. This suggested that NF-κB is indeed activated in TG2 expressing cells. 
Importantly, TG2 translocation can also be observed inside the nuclear extracts, 
indicating that TG2 might translocate to the nucleus in complex with NF-κB (since TG2 
lacks the nuclear location signal). Histones were used as control for the nuclear extracts, 
while the inhibitor of NF-κB (IκB) was used as the control for the cytoplasmic extracts.  
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Figure 15. Validation of TG2-induced NF-κB activation using immunofluorescence 
assay. 
Immunofluorescence staining of p65 subunit of NF-κB in the LNCaP empty vector, 
LNCaP-TG2, and PC-3 cells transfected with either control shRNA or TG2-shRNA. Cells 
were fixed with 3% paraformaldehyde and incubated with anti-p65 antibody. Alexa 488 
anti-rabbit IgG (green) was used to detect the bound antibody. DAPI was used to stain 
the nuclei. The LNCaP empty-vector cells revealed some localization of p65 inside the 
nucleus, while LNCaP-TG2 cells relatively showed significantly higher p65 in the 
nucleus. Similarly, PC-3 cells transfected with control shRNA, showed high levels of p65 
inside the nucleus while silencing of TG2 with TG2-specific shRNA, resulted in 
significant reduction in p65 in the nucleus. These results further confirmed that TG2 
expression results in constitutive activation of NF-κB.  
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Expression of NF-κB Target Genes in TG2 Expressing Cells 
 Using quantitative PCR, we conducted a gene array for the NF-κB target genes 
in the LNCaP, LNCaP TG2, and PC-3 cells (Figure 16). This gene array would not only 
further support whether NF-κB is activated in these cells, but also indicate which specific 
target genes were affected by the TG2-induced NF-κB activation; thereby, indicating the 
possible mechanism in which TG2 might be promoting HRPC. The LNCaP cells 
containing the empty vector demonstrate that NF-κB was not activated in these cells, as 
there is no fold change in the expression in any of the 9 tested target genes. As for the 
LNCaP TG2 cells and the PC-3 cells, we observed a significant induction of transcript 
levels, particularly in Zeb1 and Zeb2. There is about a 2500-fold increase in Zeb1 and 
300-fold increase in Zeb2 transcript levels of TG2-LNCaP and PC-3 cells. These findings 
are consistent with the RT-PCR results obtained earlier with both the cell lines (Figure 
9B). In addition, the LNCaP TG2 cells showed increase in the entire transcript levels of 
NF-κB target genes tested. The PC-3 cells shared some similarities with the TG2 
overexpressing LNCaP cells, but they still retained some distinctive characteristics. For 
example, the PC-3 cells displayed a higher transcript level of COX-2 and iNOS 
compared to the LNCaP TG2 cells. Overall, these results suggested that Zeb1 and Zeb2 
could possibly play a role in the progression of HRPC in response to TG2-induced NF-
κB activation.
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Figure 16. TG2-induced activation of NF-κB results in constitutive expression of 
downstream target genes. 
Empty vector and TG2-transfected LNCaP and PC-3 cells were analyzed for NF-κB-
induced target genes using quantitative PCR. After RNA extraction, cDNA was 
synthesized and subjected to a customized gene array kit (SABiosciences) of NF-κB 
target gene profiles. SYBR Green/Fluorescein was measured at the end of every 
annealing/extension cycle of the qPCR samples. The histogram shows fold-increase in 
indicated NF-κB target gene transcripts relative to empty vector transfected LNCaP 
cells. These results further supported the observation that TG2 expression results in 
constitutive activation of NF-κB. Notably, both TG2-transfected LNCaP as well as PC-3 
cells (with high endogenous TG2 expression), showed 2500-fold and 300-fold increase 
in Zeb1 and Zeb2 transcript levels, respectively. These results support our earlier 
observations that TG2 expression induces EMT in the prostate cancer cells. 
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Downregulation of TG2 Reconstitutes AR Expression 
 If TG2 expression results in the silencing of AR expression, we would expect to 
see that the downregulation of TG2 would restore AR expression. We used PC-3 cells, 
which contain high endogenous levels of TG2 and transiently transfected these cells with 
TG2 siRNA. After 4 days of transfection with TG2 specific siRNA, PC-3 cells were 
harvested and tested for AR expression using the western blot analysis (Figure 17). 
Unfortunately, the PC-3 cells following TG2 downregulation by siRNA appeared rather 
unhealthy, showing signs of autophagy and cell death. In comparison, PC-3 cells 
transfected with the control siRNA appeared healthy. These results indicated the 
possibility that PC-3 cells have become addicted to the TG2 regulated signaling for their 
survival and its knockdown results in spontaneous cell death. Nevertheless, transient 
downregulation of TG2 in PC-3 cells did reveal partial restoring in AR expression. It is 
possible that complete restoration of AR expression in these cells would require long-
term silencing of TG2.  
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Figure 17. Downregulation of TG2 reconstitutes AR expression.  
PC-3 cells were transfected with either control siRNA or TG2 siRNA. After 4 days, cells 
were harvested and analyzed for TG2 and AR levels by immunoblotting. We were able 
to achieve about 80% knockdown of TG2 and see partial re-expression of AR upon the 
silencing of TG2. 
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Downregulation of NF-κB also Reconstitutes AR Expression 
 Because TG2-induced NF-κB activation is essential for silencing the AR 
expression, we anticipated that the downregulation of NF-κB, particularly p65, would 
reverse the silencing and allow re-expression of AR. To test this contention, we 
transiently transfected the PC-3 cells with p65 siRNA to see if AR expression would 
return (Figure 18). We obtained about a 90% knockdown of p65 and noticed that 
transient knockdown of p65 could partially restore AR expression in PC-3 cells. 
Unfortunately, since this was only after a period of 4 days, we did not see a complete 
return of AR expression. However, we do see a faint AR band, suggesting that AR 
expression could possibly fully return if the silencing of p65 can be maintained over a 
longer period of time. 
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Figure 18. Downregulation of p65 subunit of NF-κB reconstitutes AR expression. 
PC-3 cells were transfected with either control siRNA or p65 siRNA. After 4 days, cells 
were harvested and analyzed for p65 and AR expression using immunoblotting. We 
were able to achieve ~90% knockdown of p65 in comparison with the PC-3 control 
siRNA. p65 siRNA-transfected PC-3 cells showed a partial accumulation in AR 
expression. 
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TG2 Induced NF-κB Directly Binds to the AR Promoter 
 Based on the evidence presented earlier in this document that TG2 expression 
induces constitutive activation of NF-κB and in conjunction with the earlier published 
report suggesting direct negative regulation of the AR by TNFα-induced NF-κB, we next 
wanted to see if the silencing of AR by the TG2-induced NF-κB was mediated by the 
similar mechanism. We conducted the ChIP assay to determine direct binding of TG2-
induced NF-κB/p65 to the promoter region of the AR gene. Cells extracts after 
protein/DNA crosslinking, were immunoprecipitated with anti-p65 or control IgG. 
Immunoprecipitates were tested for the NF-κB binding consensus sequences in the AR 
promoter corresponding to -38 to +246 and -760 to -460 regions (Figure 19A). Results 
shown in Figure 19B reveal that p65 directly binds to the AR promoter, but only in TG2 
expressing cells. These results clearly demonstrate that TG2-induced NF-κB directly 
binds to the androgen receptor promoter at both consensus sites and thus contributes to 
the observed TG2-mediated silencing of the AR. 
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AR Promoter (-38 to +246) 
 
GACCCGACTCGCAAACTGTTGC
ATTTGCTCTCCACCTCCCAGCGC
CCCCTCCGAGATCCCGGGGAGC
CAGCTTGCTGGGAGAGCGGGAC
GGTCCGGAGCAAGCCCAGAGG
CAGAGGAGGCGACAGAGGGAAA
AAGGGCCGAGCTAGCCGCTCCA
GTGCTGTACAGGAGCCGAAGGG
ACGCACCACGCCAGCCCCAGCC
CGGCTCCAGCGACAGCCAACGC
CTCTTGCAGCGCGGCGGCTTCG
AAGCCGCCGCCCGGAGCTGCC
CTTTCCTCTTCGGTGAAGTTTTT
AAAAGCTGCTAAAGACTCGG 
AR Promoter (-760 to -460) 
 
GGGTGATTTTGCCTTTGAG
AGTCTGGATGAGAAATGCA
TGGTTAAAGGCAATTCCAGA
CAGGAAGAAAGGCAGAGAA
GAGGGTAGAAATGACCTCT
GATTCTTGGGGCTGAGGGT
TCCTAGAGCAAATGGCACA
ATGCCACGAGGCCCGATCT
ATCCCTATGACGGAATCTAA
GGTTTCAGCAAGTATCTGCT
GGCTTGGTCATG 
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Figure 19. TG2-induced NF-κB binds to the AR promoter. 
A) Schematic representation of the AR promoter sequences. Primer sequences used for 
amplification of p65-bound region in AR promoter are shown in bold text. The putative 
NF-κB-binding sites in AR promoter are underlined.  
B) p65-bound region of the AR promoter as revealed by ChIP assay. TG2-tranfected 
LNCaP as well as PC-3 cells revealed the binding of TG2-induced NF-κB at -38 to +246 
and -760 to -460 sites in the AR promoter. The primers corresponding to the first exon of 
the AR gene served as control and did not amplify the sequence. 
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TG2 is Recruited to the AR Promoter through NF-κB Binding  
 Recently, our lab discovered TG2 and p65 interacting with each other. So, after 
identifying that p65 directly binds to the AR promoter in the TG2 expressing cells at both 
NF-κB consensus sites, we were curious to see if TG2 was possibly bound to NF-κB, 
which could then direct it to the AR promoter to induce the silencing. This time we 
conducted the ChIP assay, immunoprecipitating with anti-TG2 antibody to determine if 
TG2 was recruited to the promoter region of the AR gene as a complex with NF-κB/p65. 
The immunoprecipitates were tested using the same primers for the NF-κB binding 
consensus sequences in the AR promoter. The results reveal that TG2 is indeed 
recruited to the AR promoter by directly binding to NF-κB/p65 (Figure 20). This 
suggested that the negative regulation of the AR is modulated by TG2’s interaction with 
NF-κB. 
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Figure 20. TG2 binds to the AR promoter in complex with p65 subunit of NF-κB. 
ChIP assay was performed by immunoprecipitating protein-bound DNA complexes with 
anti-TG2 antibody. The immunoprecipitates were subjected to PCR analysis using 
primers corresponding to the NF-κB-binding site in the AR promoter. Only the TG2 
expressing cells revealed amplification of NF-κB binding sites. Primers corresponding to 
exon 1 region in the AR gene were used as negative control and failed to amplify any 
signal. 
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Chromosomal Analysis of the LNCaP Cell Lines 
Due to significant differences in the morphology and functional phenotype, 
vector-infected and TG2-infected LNCaP cells were characterized for authentication by 
chromosomal banding analysis. The karyotypic analyses for the parental, vector-
infected, and TG2-infected cells were performed in collaboration with Drs. Asha Multani 
and Sen Pathak (MD Anderson Cancer Center, Houston, TX). The chromosomal map 
for the 3 cell lines revealed that LNCaP-TG2 and vector-infected LNCaP cells were 
identical to the parental cell lines as suggested by the presence of seven marker 
chromosomes in the two cell lines. The only marker M5 on chromosome 10 (Figure 21) 
was missing in the TG2-infected cells. In addition, TG2 expressing LNCaP cells 
displayed aberrations in chromosome 11 and 15 (m1 and m2) indicating that TG2 
expression may also contribute to the genomic instability of cells. 
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 LNCaP 
 
 LNCaP E.V. 
 
 LNCaP TG2 
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Figure 21. Karyotypic mapping of LNCaP, LNCaP E.V., and LNCaP TG2 cells. 
Chromosome mapping of the 3 LNCaP cell lines. The 7 marker chromosomes (M1-M7), 
characteristics of the original LNCaP cells, were retained in the LNCaP-empty vector 
cells. The LNCaP-TG2 cells also retained all marker chromosomes, except M5. In 
addition, the LNCaP TG2 cells showed some aberrations in their chromosomes, 
depicted by m1 and m2 label. The tentative identification of the markers are as follows: 
M1- del(1p), M2- del(2p), M3- iso(5p), M4- del(6p), M5- del(10q), M6-der(15), M7- 16q+, 
m1- der(11), and m2- der(15). 
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Specific Aim 1: 
Although androgen depletion is an effective strategy for treating human prostate 
cancer [98], the emergence of hormone refractory prostate cancer (HRPC) cells pose a 
major challenge [99]. The HRPCs exhibit resistance not only to androgen ablation 
therapies, but are also more aggressive, highly metastatic, and resistant to conventional 
therapies, resulting in ultimate death of patients. Overall, prostate cancer is a very 
heterogeneous disease. Not only does it differ between patients, but even within the 
same patients [64]. Therefore, it is possible that cancer cells could use several different 
mechanisms whether initially to begin with or by a multistep progression to become 
HRPC [39]. Here we investigated the significance of tissue transglutaminase (TG2) 
expression in HRPC as TG2 has been found to promote invasion [89], metastasis [87, 
90], and drug resistance [91] in multiple-cancer types. In our preliminary data, we 
observed an inverse correlation between TG2 and AR expression. Thus, HRPC cell lines 
(PC-3 and DU-145), which lack AR expression [100], expressed high basal levels of TG2 
(Figure 3). Conversely, the androgen-dependent prostate cancer cell lines, which 
expressed high basal levels of AR, completely lacked TG2 expression. The C42B 
prostate cancer cell line with high AR expression and yet independent of androgen for 
their growth and survival also lacked TG2 expression. These findings suggested that 
TG2 could play a role in promoting HRPC through a complete bypass of the AR 
signaling pathway where these cells may utilize alternative pathways for their growth and 
survival. Therefore, our study design involved creating a stably TG2-transfected LNCaP 
cells to test the ability of TG2 expression to promote hormone refractoriness, metastasis, 
and drug resistance. We also used the PC-3 cells in conjunction with the TG2-
transfected LNCaP cells to check whether the transfected or endogenous TG2 
expression in the prostate cancer cells shared similar characteristics. The LNCaP cell 
line was originally established from a metastatic lesion of a human prostate 
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adenocarcinoma [101] and still retains sensitivity to androgen. The PC-3 cell line, on the 
other hand, was derived from a human prostatic adenocarcinoma metastatic to bone 
[102]. The PC-3 cells are androgen-independent with high metastatic potential. While 
LNCaP cells show AR expression, it has been reported that PC-3 prostate cancer line 
lacks AR expression [103, 104]. Both LNCaP and PC-3 are considered “classical” 
prostate cancer cell lines and are commonly used in the study of prostate cancer [105]. 
In our initial effort, we first confirmed the basal status of AR in various prostate cancer 
cell lines by evaluating the AR expression by immunoblotting. Using the lentiviral 
particles containing full length ORF for TG2 coding sequence, we established stable 
LNCaP cells with high TG2 expression by selection against puromycin. We were 
successful in establishing stable multiple TG2-transfected LNCaP subclones. The 
LNCaP control as well as the one transfected with the empty vector show absolutely no 
expression of TG2 (Figure 6A). We found that once transfected with TG2, these cells 
become independent of androgen for their growth and survival. Thus, neither the 
absence of androgen agonist nor the presence of antagonist affected their growth in 
culture (Figure 6B). In addition, the cell proliferation assay revealed that TG2 expression 
did not affect the overall growth rates of LNCaP cells, suggesting that the observed 
independence of TG2-expressing LNCaP cells from androgen is related to TG2-
regulated mechanism (Figure 7). 
Epithelial-to-mesenchymal transition (EMT) is a developmentally regulated 
process in which epithelial cells lose their epithelial-like characteristics and acquire the 
mesenchymal phenotype [106]. There are certain molecular factors that are involved in 
EMT and they serve as biomarkers to indicate this process: Epithelial cells are 
characterized by their high cell-to-cell contact due to the tight cell adhesion mediated by 
E-cadherin and β-catenin proteins. Mesenchymal cells show a loss in cell adhesion and 
instead show expression of fibronectin, vimentin, zinc finger E-box binding homeobox 1 
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(Zeb1), and zinc finger E-box binding homeobox 2 (Zeb2), mesenchymal markers [107]. 
While the epithelial cells are drug responsive, mesenchymal cells are drug resistant and 
display increased cell mobility [108]. Although EMT is a normal physiological process 
important in embryonic development  [106], its reactivation in adults can initiate 
pathological changes such as tissue fibrosis or increased invasion and metastasis of 
cancer cells [109]. Immobile cancer epithelial cells in the primary tumors need to 
transform to the motile mesenchymal cells in order to metastasize; therefore, EMT 
provides a mechanism that facilitates tumor progression [110]. There has been 
increasing evidence in support of EMT playing a role in cancer progression as the 
mesenchymal cells have the mobility and invasive potential to metastasize to distant 
sites [111]. The downregulation of cell adhesion molecules alters the epithelial 
homeostasis and promotes the invasiveness of cancer cells [112]. E-cadherin is one of 
the primary proteins involved in adheren junctions, providing the interaction between 
neighboring cells [113]. Loss of E-cadherin is one of the distinct features of cells 
undergoing EMT [112]. In addition, β-catenin expression and localization to the nucleus 
is an important feature associated with EMT [114]. The presence of β-catenin in the 
cytoplasm helps retain the epithelial phenotype, whereas the translocation to the nucleus 
is associated with the loss of E-cadherin expression [115]. These traits promote the 
susceptibility of cancer cells to undergo EMT and to acquire invasive ability. EMT can 
arise from the tumor-associated stroma microenvironment [116]. Notably TGF-β, which 
plays a role in controlling inflammation and tumor cell death [117], is capable of inducing 
EMT in cells by activating a series of EMT-inducing transcription factors, such as Zeb1 
and Zeb2 [118, 119]. These transcriptional repressors negatively regulate the expression 
of E-cadherin [120, 121]. Once these factors are expressed and activated, they work 
pleiotropically to facilitate the acquisition of a mesenchymal phenotype [107]. As 
mentioned earlier, TG2 expression has been associated with an increase in 
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invasiveness [89] and drug resistance [91, 122], both of which are also important 
characteristics of mesenchymal cells [112]. Based on this, we speculated that TG2 
expression may play a role in inducing EMT. In fact, there have been studies in support 
of EMT being induced by TG2 to promote invasion and metastasis in ovarian [123] as 
well as breast cancer [124]. Moreover, TGF-β a well-known inducer of the EMT is a 
potent inducer of TG2 expression [81]. Indeed, inhibition of TG2 by siRNA rendered 
mammary epithelial cells unresponsive to TGF-β-induced EMT, implying that TG2 
expression is an important event in TGF-β-induced EMT in cancer [124]. Moreover, 
recent findings support that EMT is an important step in the progression of prostate 
cancer as it assists in the progression to bone metastasis; the major cause of death 
occurring in more than 90% of prostate cancer patients [125]. As the prostate cancer 
commonly metastasizes to the bone, these epithelial cancer cells may need to transform 
into mesenchymal cells to become more motile, invasive, and drug resistant to 
translocate to the distant site [126]. Several studies have provided evidence of EMT 
playing a role in HRPC [127, 128, 129, 130, 131], where even the reversal of EMT could 
suppress the invasive and metastatic potential of prostate cancer cells [132]. All these 
reports seem to suggest and direct our attention to the potential role TG2 could play in 
promoting the hormone refractory prostate cancer by modulating EMT. Interestingly, one 
obvious difference we noticed between the LNCaP and TG2-transfected LNCaP cells 
was in their morphology (Figure 8). The LNCaP cells displayed high cell-cell adhesion, 
characteristic of epithelial cells with the cells growing clustered together, while the 
LNCaP TG2 cells grew separated from each other, revealing the loss of cell adhesion 
and portraying more of a mesenchymal phenotype. This suggested the possible role of 
TG2 expression in inducing the EMT in the prostate cancer cells. Earlier studies indeed 
support such contention and suggested that TG2 expression in ovarian and breast 
cancer epithelial cells induces the EMT as demonstrated by cadherin switch and 
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increase in invasiveness of ovarian cancer [123] as well as breast cancer [124]. These 
papers revealed that TG2-induced EMT is mediated at a transcriptional level through the 
alteration of epithelial and mesenchymal markers. One way TG2 could induce the EMT 
is through the increase in transcriptional repressor Zeb1 expression. Overexpression of 
TG2 alone was sufficient in inducing the EMT and was associated with increase 
invasiveness and resistance to chemotherapeutic drugs [124]. In this study, we found 
similar effect of TG2 expression in LNCaP cells. Thus, aberrant expression of TG2 in the 
LNCaP cells was associated with a loss in epithelial markers such as E-cadherin and β-
catenin, and gain of mesenchymal markers like fibronectin, vimentin, zeb1, and zeb2. 
These molecular trends were seen both at the protein level as determined by 
immunoblotting (Figure 9A) as well as at the transcript level as determined by RT-PCR 
(Figure 9B). The PC-3 cells with high endogenous TG2 expression, also demonstrated 
similar phenotype, showing the lack of E-cadherin expression and high expression of 
fibronectin (Figure 9). Albeit, PC-3 cells displayed high expression of N-cadherin, which 
was absent in all the LNCaP cells whether transfected or not with TG2. This suggested 
that though TG2 transfected LNCaP cells display some parallelism with the PC-3 cells, 
they still have some subtle differences. In addition, there may be other pathways 
involved that contribute to the progression of HRPC and it is not solely based on 
aberrant TG2 expression. TG2-induced EMT in LNCaP cells was not only associated 
with morphological and molecular changes but also accompanied an increase in their 
invasiveness and drug resistance. Thus, LNCaP-TG2 cells were more invasive than the 
control or empty vector infected cells regardless of the presence or absence of androgen 
(Figure 10). This further validated the observation that LNCaP-TG2 cells are resistant to 
androgen, as their invasive ability was not influenced by its presence. The drug 
response assay using increasing concentrations of Doxorubicin (0-0.1µg/ml) revealed 
that TG2 expression could confer drug resistance on LNCaP cells (Figure 11). The TG2-
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transfected LNCaP cells demonstrated significant resistance to doxorubicin-induced 
killing that was comparable to the PC-3 cells. At 0.05 µg/ml of Doxorubicin, both the 
LNCaP-TG2 cells and PC-3 cells showed 50% cell death compared to the 0.009 µg/ml 
concentration that caused half of the cells to die in the LNCaP-vector cells. Overall, our 
data suggested that TG2 expression has the ability to induce EMT as evidenced by the 
morphological changes, molecular markers, and the increase in invasiveness and drug 
resistance in the prostate cancer cells and thus may contribute to the HRPC phenotype. 
Specific Aim 2: 
 So far, we have been able to show that TG2 expression has the ability to confer 
hormone refractoriness and induce EMT in prostate cancer cells and thus, promote 
HRPC. Next, we determined how TG2 could possibly promote the HRPC phenotype. To 
address this, first, we checked the status of AR expression in TG2 transfected LNCaP 
cells. Earlier we established an inverse relationship between TG2 and AR expression. Is 
TG2 expression associated with the loss of the AR? Intriguingly, we found that the 
answer was ‘yes’. Thus, transfection of TG2 in LNCaP cells was associated with a 
complete loss in AR expression, both at protein and at the transcript level (Figure 12). 
These results explained why LNCaP-TG2 cells acquired resistance to androgen. In the 
absence of AR, these cells are able to bypass the AR signaling and probably rely on 
some alternative pathway for their growth and survival. Because TG2 is not a 
transcription factor, it is unlikely that it could directly silence AR expression. On the other 
hand, numerous studies have reported constitutive activation of NF-κB in prostate 
cancer cell lines [133, 134] and in tissue samples [135, 136]. Activated NF-κB is involved 
in controlling normal cellular processes, which include immune and inflammatory 
responses, developmental processes, growth, and survival [137]. NF-κB is maintained in 
an inactive state by its inhibitor, IκB [138]. However, once IκB is phosphorylated by IκB 
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kinase (IKK) [139], it results in the dissociation of the bound inhibitor from NF-κB, 
allowing NF-κB to be activated and translocate to the nucleus where it binds to the DNA 
and regulates transcription of specific target genes [140, 141]. NF-κB has been found to 
be constitutively activated in many types of cancers [142]. In fact, the constitutive 
activation of NF-κB has been implicated to play a role in the progression of prostate 
cancer [143, 144] and induction of EMT [131, 145, 146]. In addition, the overexpression 
of TG2 has been found to result in constitutive activation of NF-κB [147, 148]. These 
evidences suggest that the overexpression of TG2 could result in the constitutive NF-κB 
activation, which could then lead to the silencing of AR. There is further support to this 
contention: An inverse correlation between AR and the constitutive activation of NF-κB 
has been reported recently. Specifically, Rajasekhar et al. [149] identified a subset of 
stem-like human prostate tumor-initiating cells that lacked AR expression, but exhibited 
increased NF-κB activity. Most importantly, the AR promoter was found to contain NF-κB 
response element. Ko et al. [97] demonstrated that NF-κB induced by tumor necrosis 
factor α (TNFα) treatment of prostate cancer cells, resulted in the negative regulation of 
AR expression due to direct binding to the AR promoter. These studies provided 
compelling evidence and directed us to pursue the study of TG2-induced NF-κB 
activation as the potential mechanism of AR silencing in LNCaP-TG2 cells. First, we 
determined whether or not NF-κB is activated in TG2 transfected prostate cancer cells. 
EMSA (Figure 13), immunoblotting of nuclear and cytosolic protein fractions (Figure 14), 
and immunofluorescence staining (Figure 15) with anti-NF-κB p65 antibody all revealed 
that forced (LNCaP-TG2) or endogenous (PC-3) TG2 expression indeed resulted in 
constitutive activation of NF-κB. Similarly, the results from the qPCR of NF-κB target 
gene array (Figure 16) further validated the activation of NF-κB in TG2 expressing cells. 
Particularly, there was a significant increase in Zeb1 and Zeb2, transcriptional 
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repressors known to negatively regulate E-cadherin expression and promote EMT [150, 
151, 152], which is also consistent with the RT-PCR results seen earlier when studying 
EMT markers in prostate cancer cells (Figure 9B). Our data corresponds with previous 
reports of NF-κB activation in prostate cancer cells. Gasparian AV et al. [133] had 
observed that the prostate cancer cell lines that lack AR expression such as PC-3 and 
DU-145 contained high constitutive activation of NF-κB whereas the LNCaP cells, which 
are androgen sensitive, contain low NF-κB activity levels.  
If TG2 expression was directly associated with the loss of AR expression, we 
would expect to see the return of AR when TG2 is knocked down. In order to 
demonstrate this, we attempted to silence TG2 expression by transient transfection 
using TG2 siRNA in the PC-3. The cells were harvested four days after transfection. 
Downregulation of TG2 by siRNA in PC-3 cells resulted in significant cell death and 
induction of autophagy. The knockdown of TG2 was not complete, but close to around 
80%, where we can start to see the return of AR, although the expression is very faint 
(Figure 17). These results suggested that PC-3 cells become dependent on TG2-
regulated pathways (oncogenic addiction) for their growth and survival and inhibition of 
TG2 results in their spontaneous death. Nevertheless, the partial return of AR in TG2 
inhibited cells do suggest that TG2 expression is indeed an important player in silencing 
the AR expression.  Likewise, if TG2-induced NF-κB was the contributing factor in 
silencing AR expression, we would expect to see the return of AR expression when NF-
κB is inhibited. Thus, we attempted to transiently transfect PC-3 cells with p65 siRNA. 
After a period of 4 days, we were able to obtain 90% knockdown of p65 levels and do 
see the partial return of the AR expression (Figure 18). But as mentioned before, 
complete reversal of the AR may require long-term inhibition of TG2 or its downstream 
NF-κB activation. Attempts to establish a stable knockdown of TG2 or NF-κB p65 in the 
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PC-3 cells using TG2 shRNA or NF-κB p65 shRNA lentiviral particles were 
unsuccessful. Nevertheless, transient inhibition of TG2 or NF-κB do support the notion 
that loss of AR expression in TG2 expressing cells is related to TG2-induced NF-κB 
activation.  
Next, we determined if NF-κB actually binds to the NF-κB consensus sequences 
of the AR promoter as reported earlier by Ko et al. [97] Using the ChIP assay, we were 
able to establish that TG2-induced NF-κB does directly bind to the AR promoter at both 
the NF-κB consensus binding sites, -36 to +246 and -760 to -460 (Figure 19). Although 
we were unable to convincingly show that TG2 and NF-κB expression directly results in 
the silencing of AR from our knockdown experiments, Ko S et al. [97] were able to 
demonstrate a decrease in AR expression from transcriptional repression due to TNFα-
induced NF-κB as a consequence of direct binding to the AR promoter. This was 
illustrated in the LNCaP cell line where NF-κB activation was induced by TNFα. As 
previously mentioned, TG2 is a pro-inflammatory protein; therefore, cytokines such as 
TNFα that are secreted during tissue injury or wound healing are able to induce TG2 
gene expression [82]. Recently, our lab has established that TG2 forms a stable 
complex with the p65 subunit of NF-κB. This raised the possibility of TG2 interaction with 
NF-κB to potentially direct NF-κB to translocate to the nucleus where it can directly bind 
to the AR promoter leading to the silencing of AR expression. Therefore, we proceeded 
with another ChIP assay, this time immunoprecipitating with anti-TG2 antibody. 
Interestingly, we found that immunoprecipitation with TG2 also resulted in the 
amplification of both NF-κB consensus sites (Figure 20), indicating that TG2 is recruited 
to the AR promoter in complex with NF-κB/p65. This suggests that TG2 constitutively 
activates NF-κB by directly binding to it, leading to its translocation to the nucleus and 
binding to the AR promoter to negatively regulate AR expression. Further studies are 
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needed to determine whether both NF-κB consensus sites on the AR promoter are 
essential for silencing the AR expression or one site being particularly dominant over the 
other. Also, identification of other factors recruited by TG2 and p65 complex to the 
promoter of the AR and their significance in silencing its expression is of interest. In 
addition, the exploration of histone modifications responsible for the silencing of AR 
would be an interesting aspect to study in order to discover how the TG2/NF-κB complex 
may be modulating these effects. In conclusion, this work defined a novel function for 
TG2 and demonstrates, for the first time, the significance of TG2 in promoting hormone 
refractory phenotype in prostate cancer cells. The TG2-induced EMT conferred 
resistance not only to androgen depletion by silencing the AR expression but also 
conferred resistance to other cytotoxic drug like Doxorubicin and promoted invasiveness, 
important traits of HRPC (Figure 22). In view of these findings, further studies to validate 
the potential of TG2 as a novel therapeutic target for treating certain tumor/patient 
subpopulations in which TG2 expression is aberrantly upregulated is strongly warranted. 
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Conclusions and Future Directions 
Studies reported in this manuscript provide compelling evidence supporting that 
TG2 expression in prostate cancer is sufficient to confer hormone refractoriness. The 
data obtained documented that exogenous expression of TG2 in androgen-sensitive 
LNCaP prostate cancer cells could render these cells independent of androgen for their 
growth and survival. Notably, TG2 expression, whether induced or endogenous, induced 
the EMT in these cells and thus contributed to their increased invasiveness and drug 
resistance, the important traits of hormone refractory prostate cancer cells. These results 
suggest a novel mechanism for androgen independence by prostate cancer cells and 
thus warrant future studies to determine the expression of TG2 in patient samples to 
establish clinical relevance of these findings. Indeed, a recent study by Shah RB et al. 
do support such contention and suggested that a significant number of tumor samples 
from advanced stage prostate patients lacked the AR expression [64]. 
            In addition, our studies demonstrated that TG2’s ability to promote androgen-
independent growth and survival is due to the complete bypass of the AR signaling 
pathway. TG2 expression in prostate cancer cells was associated with a complete 
silencing of the AR expression.  The data obtained revealed that this silencing of AR was 
mainly due to constitutive activation of the transcription factor, NF-κB. TG2 in complex 
with the p65 subunit of NF-κB was found to directly bind to the two NF-κB binding sites 
in the AR promoter, which resulted in the silencing of its expression. However, it remains 
to be determined which of the two NF-κB binding sites in the AR promoter is critical for 
TG2/NF-κB mediated silencing of the AR expression. Similarly, future studies to 
determine the nature of co-repressors that are selectively recruited in response to 
TG2/NF-κB binding of the AR promoter will be of interest. Previous studies have 
suggested a strong link between NF-κB activation and progression of HRPC [142, 144] 
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and EMT [131, 145, 146] in prostate cancer cells. However, mechanisms responsible for 
constitutive activation of NF-κB in HRPC cells remain largely unknown. Our data fills this 
important gap and suggested that aberrant expression of TG2 in prostate cancer cells 
results in constitutive activation of NF-κB due to its interaction with the p65 subunit and 
thus, preventing its binding to the inhibitory protein IκBα. 
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Figure 22. TG2-regulated pathways during progression of hormone-refractory 
prostate cancer. 
Inflammatory signals can lead to the aberrant expression of TG2, which results in the 
constitutive activation of NF-κB due to its binding to the p65 subunit of NF-κB. This 
permits the translocation of TG2 to the nucleus in complex with p65. In the nucleus, 
TG2/p65 complex binds to the AR promoter and results in its silencing through 
recruitment of co-repressors. In addition, TG2-induced NF-κB could induce the 
expression of transcriptional repressors Zeb1 and Zeb2 by regulating the expression of 
other transcription factors such as HIF-1α and promote the EMT state in prostate cancer 
epithelial cells. EMT is known to confer drug resistance and invasiveness; hence, TG2 
expression may allow prostate cancer cells to bypass AR signaling for their growth and 
survival and induce EMT to confer drug resistance and invasiveness. 
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